Cynosure Group LLC Sells 711 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Cynosure Group LLC reduced its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 15.3% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,925 shares of the medical instruments supplier’s stock after selling 711 shares during the quarter. Cynosure Group LLC’s holdings in LeMaitre Vascular were worth $365,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LMAT. CANADA LIFE ASSURANCE Co boosted its position in LeMaitre Vascular by 44.7% during the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after purchasing an additional 6,875 shares during the period. Sequoia Financial Advisors LLC acquired a new position in LeMaitre Vascular in the 2nd quarter valued at about $1,010,000. Janus Henderson Group PLC grew its stake in LeMaitre Vascular by 554.7% in the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock valued at $3,697,000 after buying an additional 47,218 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in LeMaitre Vascular by 240.2% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock valued at $929,000 after acquiring an additional 7,976 shares during the period. Finally, Nicholas Investment Partners LP acquired a new stake in LeMaitre Vascular during the second quarter worth approximately $3,900,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Up 0.4 %

LMAT stock opened at $105.80 on Friday. The company’s 50-day moving average price is $95.18 and its two-hundred day moving average price is $87.68. The firm has a market cap of $2.38 billion, a P/E ratio of 57.81, a P/E/G ratio of 2.62 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $51.70 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.33 earnings per share. Equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 10.79% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Lake Street Capital started coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. Finally, JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $94.57.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.